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This prorpective study inrerdgated whether pretreatment with 
intravenously administered calcium would influence the erect ol 
nifedipine on rest hcmodynamics and treadmill performance in 
patients with ischemic heart disease. Sevenieen patients were 
studied a&r undrr~uing a qualifying treadmill exercise t& lhal 
rcvealcd ST segmenl depressiun indicative of isrhemic hear1 
disease. St&y subjecrs performed three additional treadmill tests 
as part ol the protwol. One treadmill test was obtatned from each 
patient to provide baseline mraserements without a preceding 
intravenous iniurion and in the absence or all antianginal drugs 
including nifedipine: two additional exercise tests were preceded 
by an inCusion and IO mg of bite-and-swallow nifedipine, The 
infusions, administered in a randomized, double.hlind, crossover 
fashion, cons&d of either ID ml aC 10% calcium chloride 
(13.6 mEq) in 50 ml of SW dextrose in water or 5% dextrose in 
water alone. 
significantly lower aCter adminirlration of nikdipine alone than 
after administration ol calcium and nifedipine (124 t 4.1 vs. 135 
* 4.2 mm Rg, p < 0.01). Peak exercise syrlollc blood pressure 
was reduced after placebo and nifedipine 1170 9 7.5 mm Hg, p < 
0.051, but not afler calcium and nifedipine, in comparison with the 
value of 178 * 8.1 mm Jig on BP baseline treadmIll lest. 
Exercise duralion waslonger (p c O.OS)lhan baselineduration 
(365 + 27 I) after pBceba and nifedipine (4!lS 3 32 s) hut was not 
slgificontly chnnyd slter calcium and nil&pine (391 f 34 6). 
Maximal ST seglnenl depression on baseline testing 0.35 I 
0.1 mm) was significantly reduced Cp < 0.05) aCter administration 
of either nifcdipine alone IO.79 * 0.1 mm) or calcium and 
nifedipine CO,85 * 0.2 mm). All 17 p&cats had ST segment 
depression on baseline exercira terllng sompared with only 12 OC 
17 subjecis after nifedipine alone and only 10 afier cskium and 
niedlpine. 
Rest syslolir blood presrurc (134 f 4.6 mm Hg) was unchanged 
after placebo infusion (135 * 4.6 mm Hg) but det?eased to 124 2 
4.1 mm Hg Cp < 0.01) 25 minaQer nifedipine administralion. Rest 
systolic blwd PPE.SW increased afler calcium inhush lfmm 139 
f 4.3 to 138 + 4.8 mm If& p < 0.01) and then d.:reased 
signifi<anly 25 min after nifedipinc administration fo 135 ? 
4.2 mm ICg (p < O.lJI). Despite a decrease at the time of peak 
nifedipine effect after either InCwion, systolic blood pressure was 
Conclorions: Calcium administration was associated with a 
sigiiicant increase in systolic tdwd pressure in patients wiih 
lschrmlc heart disease. Niiedipine reversed the increase in bled 
prersure induced by calcium but systolic pressure did nol decreeso 
below baseline values. By electrocardiographic criteria, treadmill 
performance WBT still improved compared with bavliie valuer 
when administration oCniCedlpine was preceded by cakium. 
fJ Am Coil Canfief 1!J91;18:10?0-6) 
Calctum channel antagonists. through their influence on the 
membrane transport of calcium. have a salutary effect in 
pw3.a wilh a wide variely of cardiovascular dlseaees (I). 
Druga in !his class may lessen symptoms of ischcmic hear1 
d&ease by inducing coronary vasodilation and reducing 
myocardial oxygen demand and also may lessen symptoms 
of supraventricular arrhythmia (2) by an inhibitory effect on 
sinus and atrioventricular node conduction. Despite these 
beneficial effects. colcitm channel antagonists induce signif- 
icanl peripheral varodilation. which may produce serious 
hypotension ia patients with arrhythmia or myocardial 
ischemia (3-S). Several investigators (4-101 have found that 
administralion of inrravenous calcium may reverse or pre- 
vent the unwanled reduction in blood pr:ssure induced in 
psticnts during antiarrhythmic treatment with the calcium 
channel antagonist vempamil. It is not clear whcthcr calcium 
would exert a similar effecl on the action of nifedipine. a 
calcium channel antagonisl thal has more potent vasodilator 
eRects. Although calcium administraiion does not appear to 
lessen the antiarrhythmic effectiveness of verapamd. the 
influence of this ion on the anl+ischemr wion of calcium 
antagonisa has not hccn determined. 
The present prospective study was desIgned to extend 
previous work by assessing Ihe potemial of inlmvennus 
calcium to lessen the hypotensive and am-lxhemic effecrs 
of the calcium channel antagoms! niiedlpme. Hemodynunuc 
variables were monitored in pat;en~ at re?t during a >:uJy 
prolod that called first for an infusion of c:dcIum or 
placebo, admmistered in a ran~lomizcd. double-blind cross- 
over fashion. followed by adm%lstralion of bite-and-5wallow 
nifedipine. The influence of calcium on exercise perfor- 
mance was investigared by comparing rc\ulrs of baseime 
treadmill testing without infusion or nifedipme with re\ulr5 
of treadmill tests performed after mfuxon of elthcr placcbu 
or calcium and administration of nifedipine 
Methods 
Study patienls. Subjects for the study were recruited 
from patienrs undergoing treadmill performance evaluation 
in the clinical exercise laboratory at the Univcrsi~y of North 
Carolina Hospitals. The protocol was approved hy the 
lnstirulional Review Board ofthe Universily of North Caro- 
lina on April 8. 1987. Written informed conxnl war obtained 
from all subjects before participation in the study. 
Patients were considered for inclusion in the protocol if 
they were determined to have ischemic heart disease by a 
positive result on an exercise treadmill teqt conducted in ttx 
laboratory while they were receiving no anlianginal mcdica- 
lions. Results of this qualifying test were inlerprelcd as 
positive based on electrocardiographic (ECG) criteria. in- 
cluding I) 21 mm of horizontal or downsloping ST segment 
depression from an isoelectric baseline. and 3 zl mm 
additional ST segment depression in leads with baseline ST 
segment depression. These ST segment changes had lo 
occur in the absence of lefl bundle branch block. digoxin 
therapy or IeR ventricular hypertrophy. any of which would 
have made accurate interpretation of ischemic changes on 
the ECG impossible. 
A total of 18 patients who met these criteria participated 
in the study. Patients who enrolled in the study had no 
evidence of these exclusion criteria: acute myocardial in- 
farction 42 weeks after the baseline exercise test. allergy or 
intolerance to nifedipine or inabihty IO discontmue antlangi- 
nal drugs before undergoing the treadmill tests called for in 
rhe protocol. The symptoms of all subjects remained stable 
and no subject underwent nonmedical therapy for angmn 
before enrollment and subkequent termination of the study. 
Most subjects were given anlinnginal therapy after Ihe 
baseline exercise test. d\ntiangmal treatmeru Included beta- 
adrenergic blocking agents in II patients. lopg-acting nj- 
Irates in 9 and calcium channel blocking agents in 10. 
Administration ofantianginal agents was discontinued in the 
manner necessary IO climinarc drug effccls before perfor- 
mance of the protocol. Administration of long-acting nitrates 
was slopped 224 h before exercise testing. No subject was 
receiving a sustained rcleilse calcium channel antagonist and 
all bul IWO patients diwuntinued Ihex drugs 224 h before 
Treadmilt Ierlmg. In there two patients. mfedipine wa\ last 
taken 14 ml IX h. respeclively. beforc cxcrcise. XJ :he 
reiiduai effecti of Ihe drug shuuld havs been neghgible. The 
ubjcci\ had their beta-adrenerga blocking agents discomin- 
usd 3l to 1X h before performance of the protocol. 
AH 18 hubjew completed the study without incident. One 
patient iias Tubsequently excluded from analysis after cor- 
onary anglograph! failed 10 demonstrate obstructive core- 
nary arter) disease. Evidence of coronary anery disease m 
the CUbJeCtS Included significant obstruction (270% stenosis) 
of a! Icii.,i lini m,xjtir epicardia! YCSSC! on coronary sneiog- 
raph? in I I paLien&. Four subjects had an abnomal itrex 
radionuclide venlriculogram with an erercirc.induced wall 
mouon abnarmahry consisrent with ischemia. Two patients 
were believed to have coronary disease on the basis of 
chronic 3labie angina and multiple ireadmill tes!s that were 
posiuve by ECG crirerin. 
The study group had a mean 1st~ of 62 years and I-I of Ihe 
17 subjecis were male. Evidence of symptomat~ icchemic 
heart disease wzzs present in atl 17 patients. wirh prior 
myocardial infilrction in 7 and typical evertional angma m 14. 
Exercise treadmill testing. Symprom-limited exercise 
tes1s were petiormed on a motorized lreadmill system @en- 
\ormcdicj) using the standard Bruce protocol (I I). Leads Ii. 
V, and V, were monitored continuously throughhour exercise 
and after cxcrc~zc for b min or until the ECG xturned to 
baseline level\ .A :I-lead ECG was recorded every minute 
during and for st least 6 min after exercise or until it returned 
io baseline Icvc1s. Addittonal IMead ECG recordings were 
made when ST segment changer were noted. Once the 
padent began to exercise. blood pressure and hean rate were 
measured after the 1st 2 min ofeach stapofthe protoco! and 
every 2 min after exerciSe for at leas1 6 min. A timer was 
used to mltlale Ihe protocol and the duration of treadmill 
exercise was recorded for each patient to rhe nearest second. 
Chest Pam In\enrity was graded on a scale of 1 to IO. wrh IO 
defmcd it> Ihe most severs pain the subject had previously 
experienced. Patients were instructed to immediately inform 
the invesligators of the onsel and resolution of chest pain. If 
chest pam occurred. the time IO the nearest second was 
noted. Heart rate and blood pressure were measured at Ihe 
nme signdicant ST segment depression was nored. 
Study design. Salients were studied in our excrcize Iabo- 
rarory in the General Clinic Research Center. In addition to 
the clinically indicated qualifying exercise test. the subjccIs 
underwent three additional treadmill tests as part of Ihe 
Ftudy protocol. These rests were conducted while patients 
were receivmg only protocol medications. Two exercise 
was dunng treatment were preceded by an infusion of 
calcium or placebo administered in n randomized. crossover 
fashion and followed in each case by bite-and-swallow 
nifedipine (Fig. I). These two test5 were performed in a 
consecutive fashion separated hy 1 to 6 days (mean 2.2 [ I5 of 
I7 tests were performed within ? days]). To establish base- 
lme values for exercise performance. a third rest was per- 
formed withcur a preceding intravenous infusion and in the 
absence of antiangmal medications including nifcdipinc. In 
14 of the subjects. this tcsl was obtained at the start of the 
prorocol and the randomized part of the study proceeded 
48 h later. In three subjects. this baseline exercise test was 
conducted after the randomized tests. Criteria hr ECG 
interpretation of the study treadmill exercise tests were the 
satnc as those for the qualification tesl. 
On the days of infusion. rest blood pressure and heart rate 
were determined am’ a heparin well was placed in a large 
arm vein for the administration of calcium or placebo to the 
patient. A blood sample war taken from the patient’s con- 
tralateral arm for the measurement of serum calcium by 
standard clinical chemistry techniques. The subjects were 
then given an infusion either of a solution of 10 ml of IO% 
calcium chloride (13.6 mEq) in 50 ml ofS% dextrose in water 
or of a solution of 5% dextrose in water only over approni- 
mately 20 min and heart rate and blood pressure were 
measured again. Each subject then received IO ma of nifed- 
rpine that was chewed and swallowed. This method of 
nifedipine administration was chosen as it allows more rapid 
absorption of the drug by the patient, with peak levels 
reached earlier than by the sublingual route 112). Blood 
prcssurc and heart rate were measured in each patient every 
5 min for 25 mis after the administration of nifcdipinc. A 
second blood sample was taken for determination of xrum 
calcium 25 min after nifedipine administration. The subjects 
then immediately performed symptom-limited exercise 
treadmill tests as described earlier. 
The order of infusion of calcium and 5% dextrose in water 
(the placebo for calcium) was randomized so that nine 
subjects received calcium before nifcdipinc and eight rc- 
c&cd placebo before nifedipine. Care was taken to ensure 
that the research staff who monitored the hemodynamic 
variables aud the cardiologist who supervised the exercise 
testing had no knowledge of which patients received calciultt 
and which received placebo. All medications and random- 
iration codes for the study were prepared by the Investiga- 
tional Dru8 Service of the University of North Carolina 
Hospitals Department of Pharmacy. A study pharmacist or 
nurse administered the protocol medications and conducted 
blood pressure and heart rate monitoring before the exercise 
test. The cardiologist conducting the protocol exercise tests 
was available for the patients’ safety and knew that patients 
would be receiving nifedipinc. However. the cardiologist 
was unaware of which tests were preceded by calcium or 
placebo infusion and the changes in values of the hemody- 
namic variables during the infusions. No adverse effects 
warranting disclosure of protocol medication occurred. 
Statistical analysis. Diffcrcnceb between rest hctnody- 
namics and exercise performance during the various stages 
of the protocol in the same subject were analyzed. Hemo- 
dynamic data obtained on the day of the protocol infusions 
were used to determine the effect on blood pretrure and 
heart rate of ihe administration of calcium or placebo fol- 
lowed by nifedipine. Data from the baseline treadmill test 
were compared with exercise tests performed on the days of 
infusion of calcium or placebo followed by administration of 
nifcdipine. The significance of any difference detected was 
evaluated with use of the Wilcoxan signed rank test and 
results were confirmed with use of the paired I test. Data are 
presented as mean values 2 SEM; a p value < 0.05 was 
considered significant. 
The fo(lowin~ w~riahle.s from thr rreudmill /m were 
nnalyzed: exercise duration: maximal degree of ST segment 
depression: time to onset of chest pain; time to onset of ST 
segment depression: rate-pressure product (heart rate x 
systolic blood pressure) at ST segment depression or chest 
pain, or both: blood pressure response and time for reversal 
of ST changes. The study variables of greatest interest were 
It systolic blood pressure at rest, after pmtocot infusions, 
after nifcdipine and at peak exercise; 2) exercise duration: 
and 3) magnitude and lime to onset of ST segment depres- 
sion during treadmill exercise testing. 
Results 
Effects of inhsian (Table 1). Serum calcium levels in the 
patients were similar before the infusion of placebo or 
calcium chloride. The serum level of calcium was signili- 
eantly higher than baseline values after the 20 min infusion of 
calcium chloride (9.3 z 0.1 vs. 10.8 2 0.2 mEq/liter, p < 
0.01) and was unchanged after ihe 20 min infusion of placebo 
(9.2 + 0.1 vs. 9.1 * 0.1 mEq/liter. p = NS). There was no 
significant change in heart rate during either of the infusions 
or after nifedipine administration. An increase in systolic 
blood pressure was noted after infusion of calcium but noi 
placebo. From this point on, a significant reduction was 
noted in systolic blood pressure when nifedipine was admin- 
istered after either calcium or placebo infusion. However. a 
signitifant net decrease in blood pressure from rest values 
before infusion to those after nifedipine was noted only after 
placebo (from I34 i 4.6 to 124 + 4.1 mm Hg. p < O.Olt, and 
not after calcium (from 139 2 4.3 to I35 5 4.2 mm Hg. p - 
NS). Furthermore. systolic blood preswre was significantly 
lower 25 min afrer nifedipine clone than after nifedipine and 
calcium (124 2 4.1 VS. 135 i 4.2 mm Hg. p < 0.011. 
Calcium and treadmill respona ITable 21. During the 
baseline treadmill test, significant ST segment depression 
occurred in all 17 patients and chest pain lypical of angina 
developed irr 9. The wbjecfs reached a p&k rateprc~ure 
product (peak heart rate x peak systolic blood presstrek of 
23X1 z I.553 on rhia cxcrcisc text. Sysmlic blood presrure 
immediately before exercise was Gmilar fcr the baseline and 
for the c~lcum plw nifedipine WFR Systolic preswre before 
ewrc~a m the\e nests tended to be higher than rhar of rhe 
plxcho plw nircdipine test (p = NS). The peak systolic 
blood pr:+ure during exercw after adminisw&n of pla- 
ceho plur mfedipine wa5 significantly less ihan thar seen on 
the b~xime rreadmill resr. However. when nifedipine xas 
~dmimstsrcd after calcium infusion. peak cxcrcisc blood 
prcsaurc did not differ significantly from that achic\ on the 
hayelmc IN Hear1 rate before exercise was +if~anf!y 
lowr after calaunl plus nifedipinr than !hat on the bnwline 
tat 166 5 2.4 ~5. 74 + 3.9 beatslmin. p c 0.W hut nor lower 
than that on the test conducled afrer placebo pius nifedipine 
~rc,m~~rt[. P:ak cxwcisc heart rate was snnilar for all three 
rreadmlii t?s1x. EYecci% duration \~a) significantly longer 
alter admmlcrrmion of placebo plus nifedipine compared 
with that on the bawline treadmdl tar I409 i 32 vs. 365 ? 
?l 5. p c 0 051. In CO~UXS. after adminisrration of calcium 
plus mfedlpme WN 2 3M) exercise duration was not sianif- 
icantlv lonscr ihnn the baseline value. Exercise duration did 
not d&x &iRcanlly with placebo plus nifedipine verw 
calcium plus nifedipme. 
All Ii \ubjccis developed ST segmenl deprewon diag 
noetic of whemic heart diaeax on the baseline exerf~ tes 
compared with only IO subjects after administration o 
nifedlpme pluh cAlfm and I2 slier adminislrdtion of nifed 
2.0 
ST DE? 
(mm) 
1.0 
p < 0.01 
I I emit action of nifedipine. As expected. nifedipiue alone produced a significant increase in exercise duration and a 
c < c.cs p = NS decrease in ST segment depression compared with levels 
-71 seen on the baseline treadmill test performed in the abscncc 
1 
of antianginal therapy. Analyais of treadmill responses sug- 
gested that some anti-ischemic effect of nifedipine was 
present after calcium infusion as well. Reduction in the 
degree of exercise-induced ST segment depression was 
similar whether intravenous calcium or placebo was admin- 
istered berare nifedipine. Although exe&e duration was 
significantly longer than that on the baseline treadmill lea 
or.ly after administration of nifzdipine alone. treadmill time 
V.U not significantly different on tests conducted when 
nifcd’oine was given after calcium or nlaceho infusion. Other 0 
BASELINE C&LCl”M * PLP.CEBO * 
NlFEDlPlNE NIFEDIPINE 
Figure 2. The influence of calcium or placebo infusion on maximal 
ST wgment depression observed during treadmill exercise jesting 
after mtwtaon of mfcdlpine. The p values ccmpare maxanal ST 
seamcnf dcprcssion during cxcrcisc k&g after administration 01 
calcium or placebo and nifedipine wilh that seen on the baseline 
exercise test conducted in the absence of anfianginal agents. Eler- 
tlncardiographic evidence al ischemia is reduced under both pmto- 
col condirinn5. ST DEP = ST scgmcnt dcprcssion. 
ipine plus placebo. After nifcdipine. the maximal degree of 
ST segment depression durins exercise lesling was signifi- 
cantly lower than the baseline value whether or not calcium 
was administered (Fig. 21. Examination of other indexes of 
treadmill performance (Table 2) rcvealcd that the results of 
the cxercisc test conducted after calcium and nifcdipine 
administration tended to be between those seen after nifed- 
ipine alone and on the baseline test. Because of the small 
number of subjects. conclusions concerning the effect of 
study infusions on time to onset of chest pain are unclear. 
Discussion 
Siudy findings. This study represents the first investiga- 
tion of the effects of c&rum administration on the hypoten- 
sivc and anti-isehemic actions of nifedipine in patients with 
ischemic heart disease. Pretreatment with calcium was as- 
sociated with a slgniiicant increax in sya!olic blood pressure 
but no change occurred in this variable afier placebo infu- 
sion. Subsequent administration of nifedipinc was associated 
with a significant decrease in systolic blood pressure in the 
presence or absence of calcium. but rest systolic blood 
pressure decreased to values brlow baseline only when 
nifcdipinc was administered after placebo infusion. Like- 
wise. peak exercise blood pressure was reduced compared 
with that on the baseline exercise test afier administration of 
nifedipine alone but was unchanged after calcium and nifcd- 
ipine. 
Analysis of the study results permits preliminary assess- 
mcnt of the effect of calcium administration on the anti-isch- 
icdexes suggested a trend for e&se performance after 
calcium and nifedipine to be between that achieved on 
treadmill tests performed at baseline and after nifedipine 
alone. The limited number of subjects in the present study 
may have obscured these differences. Study of a larger 
patient group will be required to resolve this issue. 
Previous work: influence of eakiumon hypatenswe e&ctaf 
verapamil. Several investigators (4-10) have documented 
the potential of calcium to reverse the hypotension that may 
follow the administration of the calcium antagonist veta- 
pamil in the treatment of atrial tachyarrhythmia. Lipman et 
al. (4) first reported this phenomenon in a patient who 
developed atrial tibrillation 3 days after a myocardial infarc- 
tion. Verapamil administration resulted in severe hypoten- 
sion but the patient’s blood pressure returned to baseline 
values after 2 ampules of calcium chloride were given over 
I5 min. A similar case was reported by Morris and Gold- 
schlager (5). Weiss et al. (6) noted that administration of 
verapamil in a patient with atrial tachyarrhythmia resulted in 
a predictable decrease in systolic pressure. a hemodynamic 
effect that was reversed by administration of calcium. In 
addition, they found that Calcium pretreatment prevented a 
decrease in blood pressure after verapamil administration. 
The interaction of verapamil and calcium in the treatment of 
multifocal atrial tachycardia was reported by Salerno et al. 
(71, who studied 16 consecutive patients, 5 of whom were 
pretreated with calcium gluconatc. Although systolic blood 
pressure decreased in both groups after verapamil, the 
reduction was greater in the patients who did not receive 
calcium. More recently, Barnett and Touchon (8) reported 
no significant change in mean arterial pressure after admin- 
istration of calcium and verapamil in 19 patients with atrial 
arrhythmias. 
In a nonrandomized sequential study, Haft and Habbab 
(9) examined the hypotensive and antiarrhythmic efficacy of 
the administration of vcrapamil preceded by calcium in two 
groups of patients wiih atriat fibrillation and gutter. One 
group received verapamil alone: the other received calcium 
chloride before the administration of verapamil. Mean sys- 
tolic blood pressure decreased significantly in patients 
treated with verapamil alone but did not change in patients 
pretreated withcalciumchloride. Heart rate decreased to the 
same degree in all pilticnts after vsrapamil administrarmn 
irrespective of calcium prerrearment. Systolic blood prev 
sure decreased to < 100 mm Hg in 29% of patients treated 
without calcium but in none pretreated with calcium. Hari- 
man et al. (IO) studied the reversibility of verapannl-mduced 
hemodynamic and electrophysiologic changes in a dog 
model. They noled that an increase of I to 2 mEq/liler m 
serum calcium abolished the depressive effect of vcrapamil 
on cardiac function and diminished drug-related hyppten- 
sion. These actions of calcium occurred without an effect on 
the electrophysiologic actions of verapamil. These studies 
indicate that calcium can dimitnsh or prevcnr the hypoten- 
sive effect of verapamil without interfering with the antiar- 
rhythmic action of the drug. 
Mechanism of calcium’s hypertensix e&t. Although our 
work cannot define the mechanism. the increase in systolic 
blood pressure we observed after calcium administration has 
been reported by other investigators. The work of Suzuki 
and Aoki (13) offers one potential explanalmn for the hyper- 
tensive Sxt of calcium seen in the present study. These 
workers studied the hcmodynamlc responses of 32 ncr- 
ntotensive and hyperlensive subje& during a l-h infusion of 
calcium gluconate. Serum calcium levels increased in both 
groups, as did systolic blood pressure. In a subset of 16 
patients who were monitored hemodynamically during CBI- 
cium infusion. tolal peripheral resistance increased but car- 
diac output did not change, thus suggesting that the hyper- 
‘ens& effect of calcium resulted from an increase in 
peripheral vascular tone as opposed to a positive inotmpic 
effect on the myocardium. These investigators (13) also 
found in a subgroup of 12 patients that simultaneous admin- 
istration of verapamil inhibited increases in both ryslolic 
blood pressure attd tota’ peripheral resistance during calcium 
infusion. 
In the present randomized and placebo-controlled study. 
calcium had an effeecl on the hypotensive action of nifedipine 
similar to that seen with verapamil. This similarity was noted 
despite evidence that suggests tnat nibdipine is a more 
potent vasodilator than verapamil and may differ somewhat 
in mechanism of action (14). Previous work specifically 
investigating the influence of calcium on the actions of 
nifedipine is scant but the results of the present study are 
supported by the work of Morris et al, 115). who studied 
porentiation by nifedipine and diltiazem of the hypolensivc 
response commonly induced by contrast angiography. They 
showed that the decrease in blood pressure after hulur 
injection of ionic contrast medium at angiography was more 
profound and prolonged in patients who were receiving 
nifedipine ordiltiazem. In contrast. patlcnts who rcccivcd an 
injection of a nonionic agent. wltich dorb nut lower hum 
calcium levels, did not have an exaggerated hypotcnsivc 
response during concomitant therapy nnh nifedipine. Thehe 
data suggest a relation between the level of hum calcium 
and the hypotensive cffcct ofnifedipine trcan~~ent similar to 
that described in our work. 
Study implications. Our re~lrs may have practical appli. 
cation r&cd to the use of nifedipine in patienrs with acute 
lschemic heart disease. This drug reduces calcium ton move- 
ment mto mroudrdial and vascular smoorh musc!c cells 
(16.171 to promote coronary vasodllation and decrease sys- 
termc vabcuiar resistance. These hemodynamic cBects USU- 
ally XI \lmultaneously to reduce myocardial work load and 
to improve myocardial perfusion. Many placebo-controll~. 
randomized %tndies (I ,181 have demonstrated that adminis- 
tration of these agent5 improves treadmill performance and 
reduce5 h)Qolic and diastolic arterial blood pressure m 
paticnta v+llh coronary artery disease. Despite these salutzy 
effects. mfedlpine may increase myocsrdial ischemia by 
producing vS~~ern systemic vasodilalion to reduce core- 
nary pcrfu,iun pressure or to induce reflex tachycardia. In a 
large retrocpeclive study in which investigators Nrerc aware 
of pallent data. Stone et al. 119) found that 14% of 716 
patlent rcpvted an increase in angina1 symptoms during 
treatment with mfedipine. Bode” el al. (3) described the 
hazard of nifedipine-induced hvpotenqion even when reflex 
rachycardia wan pr~emed by admini~~rdlion ul a beta- 
adrenerta blocking agem. 7;~: ~rudied a group of patients 
who regularly reported angina pectons Ailin 10 to 20 min 
after oral ingestion of rufedipine: ttns change wus associated 
with a decrease in mean systolic blood pressure from 109 to 
!M mm HS and no chnnze in heart rate. The authors 13~ 
hypotbe .ired that although the rate-pressure producr de- 
crea~d during sympromstic eptsodes. myocardial is&e& 
developed hews; of a ~educdon in co<onary artc,y prfu- 
sion. Although such advtrsc consequences ofnifcdipine may 
he lessened by the use of one of rhe nei i.‘r sastained release 
formulations that slows the onset of nemodynamic effects. 
rapid induction ofnifedipine action by tl bite-and-swallow 
approach 1% shll often sought in the setting of acule Ischenna. 
The present study results indicate that pretreatment with 
mtmvcnous calcmm in doses similar to those used to reverse 
the hypotenrion assofiated with verapamil prevented the 
hypolcnsivc clfcct of nifedipine. In the clinical setling. 
treatment with calcium would he especially artracdve it’ the 
hypoten\lve bur not the anti-ischemic effects of nifedipine 
were rcvcrsed. Analysis of the treadmill test results from our 
study su_ggeat a continued beneficial effect of nifedipine on 
exercise pcrfurmance despile calcium pretreatment. which 
suggests rhrt calcium might offer a useful way to ameliorate 
symptomatic hypotension induced by nifedipine in palients 
wilh ang~~a. 
Limitations. The potential limitation5 of the present 
study mual bc addrcsscd. Some caution must he applied fo 
the interpretation nf the treadmill test dala. The baseline 
enercivz tebt. although performed in the absence of nifedi- 
pine. WI% not conducted with a trtie placebo lest because 
ncilhcr an intravenous dexfrose infusion nor a bhc-and- 
swallow placebo was given before exercise. However. the 
IWT on the Infusion days do provide direct assessment of 
the influence of calcium on nifedipine-mediated changes in 
exercise performance. More subtle differences in lreadmill 
,csimg bctwecn ihc two infusion protocols might have been 
dcuxwd had a larger number of wbjec,s been resred. The 
dose (1, -aLurn chloride used in this protocol war arbitrary 
because the effect on the blood pressure response to admin- 
iwntion of 10 mg of bi,e-and-wallow nifedipine had not 
been studied. WC chose the standard dose used lo reverse or 
prevenr a hypotrnsire recponse IO Adm;nis!ration ofintraw 
nou verapamil given i,s apparem safety and efficacy in 
published reports. The present study does not provide data 
on the possiblc &CIS of higher doses of in,ravcnous cal- H Blmee JC. Tutlchon RC. Shofl-term CO”VO, or wpmve”lricu!dr t&y. 
cium on the hwotensive and anti-ischemic effect of nifedi- cardia wilh velapdmil mlusion and calcium prcircnmcm. Chest lYX@7: 
pine. nor can we speculate as to what the results migh, have 
been if calcmm had been admimstered after nifedipk. 
Additional studies in oatients sukrinc from more snvere 
‘w-y 
9. Hafr J,. Habbab MA T~amxnt of aria1 arrhylhmiar: eff~c~ivenerr of 
vempamil when preceded by cak~um mfurmn. Arch Infern Med 1986: 
I& 10~5.9. 
myocardial ischemla will be necesrary to estabhsh the safety 10. Har~mirn RJ. Milngwdi LM. McAlhrwr RG. Surawcr 8. Shabetai R. 
and utility of calcium treatmcn, i,. alleviating hypownsivc K~+idz 3. Revenulof the cardiavascul~reN~cI~oivcra~m~l by calcium 
cumplicalions aarvciated with nifedipine therapy. 
and sodium: d~&rcnces brlween electrophysiologic and hemodynamic 
TFI~OTIICI. Cmularion 1979.59:797-804 
Conclusion. The study results indicate that calcium given I I Rrlwr VA K 5umi F. Hosmc,- 0. Maxima, oxygen iniakc wd noma- 
in a dose reported to abolish the hypotensive effect of graphic arnewnen, of fun&n?. aerobic Impair&em in sardmvascutar 
verapamil reduces the hypotensive action of nifedipine at lJi%aw. Am “earl J IY,M5’146-hZ 
rest and al peak exercise in patients with ischcmic heart I?. McAllirrer RG Jr. Kinetics and dynamics of nifediwe afler oral and 
disease. Some improvement in treadmill exercise perfor- 
iubl~n~llal darer. Am J Med lY8h:Bl~suppl bp.):!->. 
mance was noted after nifedipine administration despite the 
13. Suuki T. Aoki K. Hypenensive eKeas af cakium infusion in subjects 
wh oormo?cns~on and hvoencnrion. J Hvoenrnr 1988.6:1oOW3. 
hemodynemic etkctr of calcium. 
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